These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 6762457

  • 1. [A study of urokinase lysis time in patients with various renal diseases].
    Shimizu K, Kishi T, Ootaka M, Yamamoto J, Shibata M, Ban I, Sakai H, Kobayashi K.
    Nihon Jinzo Gakkai Shi; 1982 Nov; 24(11):1233-41. PubMed ID: 6762457
    [No Abstract] [Full Text] [Related]

  • 2. [Studies on the fibrinolytic therapy in patients with various renal diseases. Clinical effects of urokinase (author's transl)].
    Takasaki H, Shibata M.
    Nihon Jinzo Gakkai Shi; 1981 Sep; 23(9):1271-80. PubMed ID: 7035725
    [No Abstract] [Full Text] [Related]

  • 3. [In vitro study of a human plasmin (CY 218) and its association with urokinase (author's transl)].
    Brochier M, Griguer P.
    Rev Med Brux; 1981 Mar; 2(3):167-74. PubMed ID: 6453415
    [No Abstract] [Full Text] [Related]

  • 4. [Studies on coagulation and fibrinolysis. III. Urokinase activated fibrinolysodynamicogram].
    Hu YM, Xue H, Wang KQ.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1982 Jun; 4(3):133-6. PubMed ID: 6215134
    [No Abstract] [Full Text] [Related]

  • 5. [In vitro measurement of fibrinolysis by urokinase].
    Senf L.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981 Jun; 108(6):819-21. PubMed ID: 6176506
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 7. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
    Thorsen S.
    Dan Med Bull; 1977 Oct 30; 24(5):189-206. PubMed ID: 908205
    [No Abstract] [Full Text] [Related]

  • 8. Leukocyte-plasma interaction in fibrinolysis. A new dimension in the action of urokinase.
    Moroz LA, Sniderman AD, Marpole DG.
    N Engl J Med; 1979 Nov 15; 301(20):1100-4. PubMed ID: 158709
    [No Abstract] [Full Text] [Related]

  • 9. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
    Thorsen S, Astrup T.
    Thromb Diath Haemorrh; 1974 Dec 31; 32(2-3):306-24. PubMed ID: 4281113
    [No Abstract] [Full Text] [Related]

  • 10. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
    Lipinski B, Gurewich V, Hyde E.
    Thromb Diath Haemorrh; 1975 Sep 30; 34(1):351. PubMed ID: 1188799
    [No Abstract] [Full Text] [Related]

  • 11. Immunohistochemical and histochemical investigations on in vivo thrombolysis with urokinase in rabbits.
    Hisano S, Sueishi K, Ishii Y, Tanaka K.
    Thromb Haemost; 1979 Jun 30; 41(4):796-803. PubMed ID: 483251
    [Abstract] [Full Text] [Related]

  • 12. [Low molecular weight heparin and high and low molecular weight urokinase in fibrinolysis in vivo].
    Badimón L, Villaverde CA, Vidal M, Valdecasas FG.
    Arch Farmacol Toxicol; 1979 Dec 30; 5(3):262-4. PubMed ID: 397803
    [No Abstract] [Full Text] [Related]

  • 13. [Fibrinolytic system in patients with nephrotic syndrome].
    Andreenko GV, Poliantseva LR, Smirnova TA, Podorol'skaia LV.
    Ter Arkh; 1976 Dec 30; 40(2):89-99. PubMed ID: 135367
    [No Abstract] [Full Text] [Related]

  • 14. [Heparin and urokinase interactions in the fibrinolytic system].
    Villaverde CA, Badimón L, Badimón JJ, Valdecasas FG.
    Arch Farmacol Toxicol; 1979 Dec 30; 5(3):268-9. PubMed ID: 397804
    [No Abstract] [Full Text] [Related]

  • 15. [Various aspects of the platelets-urokinase interaction].
    Bastida E, Villaverde CA, Borruel MT, Valdecasas FG.
    Arch Farmacol Toxicol; 1979 Dec 30; 5(3):270-1. PubMed ID: 397805
    [No Abstract] [Full Text] [Related]

  • 16. Proceedings: Release of fibrinolytically active compounds during platelet-UK interaction.
    Koch M, Binder B, Auerswald W.
    Thromb Diath Haemorrh; 1975 Sep 30; 34(1):318. PubMed ID: 1188724
    [No Abstract] [Full Text] [Related]

  • 17. Influence of thrombolytic treatment on natural inhibitors of coagulation-fibrinolysis, with report of pulmonary embolic cases.
    Hasegawa H, Nagata H, Murakoshi T, Yamauchi M, Oguma Y, Kamishima K, Murao M.
    Nihon Ketsueki Gakkai Zasshi; 1979 Feb 30; 42(1):79-83. PubMed ID: 425795
    [No Abstract] [Full Text] [Related]

  • 18. The inhibitory effect of plasma inhibitor on plasmin activated with streptokinase or urokinase.
    Sumi H, Takada Y, Takada A.
    Nihon Seirigaku Zasshi; 1977 Feb 30; 39(5):112-4. PubMed ID: 72149
    [No Abstract] [Full Text] [Related]

  • 19. Comparative study of different urokinase preparations.
    Millar WT, Smith JF.
    Thromb Res; 1983 Jun 01; 30(5):425-9. PubMed ID: 6351343
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of vitreous clot lysis by urokinase: mode of action.
    Forrester JV, Edgar W, Millar W, Prentice CR, Williamson J.
    Exp Eye Res; 1982 Jun 01; 34(6):895-907. PubMed ID: 6211365
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.